Latest Insider Transactions at Recursion Pharmaceuticals, Inc. (RXRX)
This section provides a real-time view of insider transactions for Recursion Pharmaceuticals, Inc. (RXRX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of RECURSION PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of RECURSION PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 04
2022
|
Ramona Doyle Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
981
-1.0%
|
$10,791
$11.4 P/Share
|
|
Feb 04
2022
|
Ramona Doyle Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,891
+15.52%
|
-
|
|
Feb 04
2022
|
Shafique Virani Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,114
-1.05%
|
$12,254
$11.4 P/Share
|
|
Feb 04
2022
|
Shafique Virani Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
42,943
+15.22%
|
-
|
|
Jan 31
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
19,858
-45.83%
|
$218,438
$11.73 P/Share
|
|
Jan 31
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
19,858
+31.43%
|
-
|
|
Jan 31
2022
|
Ramona Doyle Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,625
+21.42%
|
$31,250
$2.48 P/Share
|
|
Jan 14
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
254,000
-91.54%
|
$3,302,000
$13.57 P/Share
|
|
Jan 14
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
254,000
+47.79%
|
-
|
|
Jan 13
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
87,000
-49.03%
|
$1,218,000
$14.61 P/Share
|
|
Jan 13
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
87,000
+44.06%
|
-
|
|
Jan 04
2022
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
9,625
-0.13%
|
$173,250
$18.03 P/Share
|
|
Jan 03
2022
|
Zachary Bogue Director |
BUY
Grant, award, or other acquisition
|
Direct |
589
+30.07%
|
-
|
|
Jan 03
2022
|
Blake Borgeson Director |
BUY
Grant, award, or other acquisition
|
Direct |
555
+0.01%
|
-
|
|
Jan 03
2022
|
Terry Ann Burrell Director |
BUY
Grant, award, or other acquisition
|
Direct |
763
+0.56%
|
-
|
|
Jan 03
2022
|
R. Martin Chavez Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,040
+10.71%
|
-
|
|
Jan 03
2022
|
Robert Hershberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
693
+8.1%
|
-
|
|
Jan 03
2022
|
Dean Y Li Director |
BUY
Grant, award, or other acquisition
|
Direct |
659
+0.11%
|
-
|
|
Jan 03
2022
|
Ramona Doyle Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,322
+50.0%
|
$80,644
$2.47 P/Share
|
|
Dec 21
2021
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
9,625
-0.13%
|
$173,250
$18.75 P/Share
|
|
Dec 16
2021
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
200
-0.85%
|
$4,000
$20.0 P/Share
|
|
Dec 16
2021
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
200
+0.84%
|
-
|
|
Dec 16
2021
|
Tina Marriott Larson President and COO |
SELL
Open market or private sale
|
Direct |
2,500
-1.69%
|
$47,500
$19.01 P/Share
|
|
Dec 13
2021
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
100
-0.42%
|
$2,000
$20.02 P/Share
|
|
Dec 13
2021
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
100
+0.42%
|
-
|
|
Dec 09
2021
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,086
-4.42%
|
$21,720
$20.01 P/Share
|
|
Dec 09
2021
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
1,086
+4.24%
|
-
|
|
Dec 08
2021
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
10,664
-18.51%
|
$213,280
$20.15 P/Share
|
|
Dec 08
2021
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
5,488
+15.93%
|
-
|
|
Dec 08
2021
|
Christopher Gibson Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
28,646
+50.0%
|
$57,292
$2.47 P/Share
|
|
Dec 07
2021
|
Lux Ventures Iv, L.P. |
SELL
Other acquisition or disposition
|
Direct |
4,265,576
-24.67%
|
-
|
|
Dec 07
2021
|
Zavain Dar Director |
BUY
Other acquisition or disposition
|
Direct |
3,599
+50.0%
|
-
|
|
Dec 07
2021
|
Dean Y Li Director |
SELL
Open market or private sale
|
Indirect |
15,900
-0.6%
|
$318,000
$20.75 P/Share
|
|
Dec 07
2021
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
9,625
-0.04%
|
$192,500
$20.4 P/Share
|
|
Dec 07
2021
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
3,125
-1.04%
|
$62,500
$20.78 P/Share
|
|
Dec 07
2021
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
16,667
-0.1%
|
$333,340
$20.75 P/Share
|
|
Nov 21
2021
|
Christopher Gibson Chief Executive Officer |
BUY
Bona fide gift
|
Indirect |
1,100,000
+50.0%
|
-
|
|
Nov 21
2021
|
Christopher Gibson Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
1,100,000
-11.81%
|
-
|
|
Nov 19
2021
|
Dean Y Li Director |
SELL
Open market or private sale
|
Direct |
13,474
-2.28%
|
$269,480
$20.2 P/Share
|
|
Nov 18
2021
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
9,625
-0.06%
|
$173,250
$18.68 P/Share
|
|
Nov 18
2021
|
Tina Marriott Larson President and COO |
SELL
Open market or private sale
|
Direct |
2,500
-2.4%
|
$47,500
$19.01 P/Share
|
|
Nov 17
2021
|
Dean Y Li Director |
SELL
Open market or private sale
|
Direct |
5,626
-0.94%
|
$112,520
$20.04 P/Share
|
|
Oct 01
2021
|
Dean Y Li Director |
BUY
Grant, award, or other acquisition
|
Direct |
543
+0.09%
|
-
|
|
Oct 01
2021
|
Blake Borgeson Director |
BUY
Grant, award, or other acquisition
|
Direct |
457
+0.01%
|
-
|
|
Oct 01
2021
|
Zachary Bogue Director |
BUY
Grant, award, or other acquisition
|
Direct |
295
+27.42%
|
-
|
|
Oct 01
2021
|
Robert Hershberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
572
+7.39%
|
-
|
|
Oct 01
2021
|
Terry Ann Burrell Director |
BUY
Grant, award, or other acquisition
|
Direct |
629
+0.47%
|
-
|
|
Oct 01
2021
|
R. Martin Chavez Director |
BUY
Grant, award, or other acquisition
|
Direct |
858
+10.11%
|
-
|
|
Jul 01
2021
|
Zachary Bogue Director |
BUY
Grant, award, or other acquisition
|
Direct |
295
+50.0%
|
-
|
|
Jul 01
2021
|
Terry Ann Burrell Director |
BUY
Grant, award, or other acquisition
|
Direct |
382
+0.29%
|
-
|